SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Rodrigues NB, McIntyre RS, Lipsitz O, Cha DS, Cao B, Lee Y, Gill H, Lui LMW, Cubała WJ, Ho R, Shekotikhina M, Teopiz KM, Subramaniapillai M, Kratiuk K, Mansur RB, Rosenblat JD. J. Sleep Res. 2022; 31(1): e13400.

Copyright

(Copyright © 2022, European Sleep Research Society, Publisher John Wiley and Sons)

DOI

10.1111/jsr.13400

PMID

34137095

Abstract

Sleep disturbances are commonly reported in patients with treatment-resistant depression (TRD). Available data have shown that intravenous (IV) ketamine is an effective treatment for patients with TRD and growing data suggest ketamine may improve overall sleep architecture. In the present study, we evaluated whether changes in sleep symptoms mediated the anti-depressive and/or anti-suicidal effects of IV ketamine and whether improvement in sleep correlated with a higher likelihood of achieving response or remission. Adults with TRD received four infusions of IV ketamine at a community-based clinic. Total depressive symptom severity was measured with the Quick Inventory Depressive Symptoms Self-Report 16-Item (QIDS-SR16 ) at baseline and was repeated across four infusions. Suicidal ideation (SI) and four sleep symptoms were measured using the SI item and the five sleep items on the QIDS-SR16. A total of 323 patients with TRD received IV ketamine. Self-reported improvements in insomnia, night-time restlessness, hypersomnia, early morning waking, and total sleep were significant partial mediators to the improvements observed in depression severity. Similarly, insomnia, night-time restlessness, early morning waking and total sleep improvements mediated the reduction of IV ketamine on SI. All sleep items, except for hypersomnia, were associated with an increased likelihood of achieving response or remission. Notably, each point improvement in total sleep score was significantly associated with achieving responder/remitter status (odds ratio 3.29, 95% confidence interval 2.00-5.41). Insomnia, sleep restlessness, early morning waking and total sleep improvements were significant mediators of antidepressant and anti-suicidal improvements in patients with TRD receiving IV ketamine.


Language: en

Keywords

Humans; Adult; Sleep; Depression; Suicidal Ideation; bipolar disorder; ketamine; sleep; major depressive disorder; Ketamine; Depressive Disorder, Major; treatment-resistant depression; CRTCE

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print